P/B
5,6
AstraZeneca
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.
$289.4B
Market Cap • 11/2/2026
1992
(34 years)
Founded
NYSE
Listing Exchange
United Kingdom
Country
Valuation
P/S
4,6
P/EBITDA
13,7
P/OCF
21,9
P/FCF
28,3
P/E
26,4
BVPS
33,4
EPS
7,1
Market Cap
Market Cap
289,4B
EV
315,5B
EV/Revenue
5,1
EV/EBITDA
14,9
EV/EBIT
21,4
Payout
Dividend Per Share
3,2
Dividend Yield
1,7%
Buyback Yield
0,3%
Total Yield
2%
Dividend Yield 5Y
1,9%
Payout
45%
Retained Earnings
14,1B
Profitability
Gross Margin
81,9%
EBITDA Margin
34%
EBIT Margin
23,7%
Net Margin
17,7%
D&A/EBITDA
0%
R&D/Revenue
24,5%
Capex/Revenue
4,8%
Capex/D&A
47,1%
Capex/OCF
22,8%
SBC/OCF
—
% PPE
14%
% Goodwill
17,6%
ROE
22,6%
ROIC
13,3%
Growth
CAGR Revenue 5Y
13,7%
CAGR Op. Income 5Y
39,1%
CAGR Net Income 5Y
49,7%
CAGR EPS 5Y
40,7%
CAGR OCF 5Y
15,8%
Leverage
N.D./EBITDA
1,2
Debt/Equity
0%
Current Ratio
1
Quick Ratio
0,7
Interest Coverage
825,9%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!